T3D-959: A Multifaceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease

Manuscript Number: 

15-1013R1

Author(s): 
Chetram Deochand, John Didsbury, Ming Tong, Suzanne M. de la Monte

Disclosures

Suzanne M. de la Monte

  • Equity:
    Stock options in T3D Pharmaceuticals

Chetram Deochand

  • Nothing to Disclose

John Didsbury

  • Equity:
    Common and Preferred Stock equity ownership as Company Founder; 36% ownership
    Sponsors:
    CEO of T3D Therapeutics

Ming Tong

  • Nothing to Disclose